Core Insights - Stereotaxis (STXS) announced initial clinical results for its MAGiC catheter, marking the first peer-reviewed evidence of its safety and efficacy in treating cardiac arrhythmias [1][4] - The MAGiC catheter is the first robotic, fully integrated radiofrequency ablation catheter designed for use with Stereotaxis' Robotic Magnetic Navigation system, demonstrating consistent navigation accuracy and a strong safety profile [2][4] Company Performance - Following the announcement, STXS shares remained flat, with a year-to-date decline of 3.5%, compared to the industry's 7.4% decline and the S&P 500's gain of 6.3% [3] - The company currently has a market capitalization of $189.2 million [6] Clinical Study Results - The MAGiC catheter study involved 67 patients, showing an acute efficacy rate of 94% and a low procedure-related adverse event rate of 1.5% [7][8] - The study reported no adverse events linked to catheter malfunction, with an average procedure time of 83 minutes [8] Technological Advancements - The MAGiC catheter demonstrated improved stability, steady tip temperatures during ablation, and low irrigation rates, enhancing safety and efficiency in robotic ablation procedures [9] - These advancements are expected to boost physician confidence and accelerate the adoption of Stereotaxis' robotic system [4] Industry Outlook - The global market for robotic catheterization systems is projected to grow from $54.4 million in 2025 to $190.2 million by 2035, driven by the demand for minimally invasive procedures [10][11]

RT Biupa-TZC (@biupa)BONKBTC weekly double bottom@theunipcs thoughts https://t.co/LY7okzfefp ...

I think we just start with the basics, James, if we can. Why did you write that open letter to test this board. And why do you think they need to understand the formation of the America Party in the context of whether or not is a benefit to the company and Tesla's future goals.Well, good morning, Ed. The truth is that when you have a full time CEO in Elon Musk, who has been an extraordinary CEO, his time and energy needs to go to Tesla and synergistic companies like X, AI or Space X, a political party, rega ...

Core Insights - Intuitive Surgical (ISRG) received CE-mark approval for its latest surgical robot system, da Vinci 5, which includes over 150 enhancements aimed at improving surgical outcomes and operational efficiency [1][2] - The da Vinci 5 system is cleared for minimally invasive endoscopic procedures across various specialties, expanding Intuitive Surgical's clinical reach in Europe [2][7] - The surgical robots market in Europe is projected to grow from $1.89 billion in 2024 to $3.31 billion by 2030, with a CAGR of 10.3% from 2025 to 2030, driven by technological innovation and increasing chronic conditions [4] Company Developments - The da Vinci 5 system offers 10,000 times more processing power than earlier generations, integrating advanced sensors and software for real-time insights to improve surgeon performance [3] - In Q1 2025, 147 out of 367 da Vinci systems placed globally were da Vinci 5 units, indicating strong demand in the U.S. market [5][7] - The adoption of force feedback instruments in da Vinci 5 procedures has shown significant clinical benefits, including faster recovery times and improved surgical proficiency [5] Market Performance - Intuitive Surgical's performance in Europe remains strong, with 88 earlier versions of da Vinci systems placed in Q1 2025, and over 410,000 procedures performed in 2024 [8] - Despite macroeconomic pressures, the company continues to focus on training and operational optimization to support procedural growth [8][14] - ISRG's stock has gained 18.9% over the past three months, outperforming the industry average of 14.3% [10] Competitive Landscape - Intuitive Surgical faces competition from companies like Medtronic and Stryker, with Medtronic's Hugo system being 20-25% less expensive but noted for a steeper learning curve [9] - Stryker's Hugo leads in orthopedic robotic surgery, indicating a segmented competitive landscape [9] Financial Outlook - The Zacks Consensus Estimate for ISRG's earnings per share has been revised downwards for 2025 and 2026, reflecting rising costs associated with the launch of da Vinci 5 [6] - ISRG is currently trading at a forward price-to-earnings multiple of 64.32X, higher than the industry average of 28.81X, but lower than its five-year median [15] Long-Term Prospects - The CE mark approval for da Vinci 5 opens significant revenue potential in Europe's growing surgical robotics market [15] - Despite near-term challenges, ISRG's dominant market share and focus on innovation position it well for long-term growth [15]

Example video of a robot in existence, operating as intended:https://t.co/SiqWeC6E9L ...

Robots won't be for everyone, at least for now.But physical AI will become interwoven with the fabric of society in the medium term.Either adapt and adopt, or become the Grandma still trying to figure out how to switch the computer on.Ansem (@blknoiz06):i do not want a robot in my home folding my clothes bro ...

KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy, is pleased to announce the appointment of Mr. Alex S K Chua as Executive Director of VCIG and Chief Executive Officer of VCIG Singapore Office, effective July 7, 2025. Mr. Chua has resigned from his role as Independent Director and has ...

GUANGZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- AIFU Inc. (Nasdaq: AIFU) (the “Company” or “AIFU”), a leading AI-driven independent financial services platform in China, today announced that it has entered into a definitive share purchase agreement (the “Agreement”) with certain investors, pursuant to which the investors have agreed to subscribe for, and the Company has agreed to issue and sell to the investors, (i) an aggregate of 10,000,000 Class A ordinary shares, par value US$0.4 per share, of the C ...

机器人产业蓬勃发展，正极大改变着人类生产和生活方式，为经济社会发展注入强劲动能。2023年年 初，工业和信息化部联合十六大部委印发《"机器人+"应用行动实施方案》，目标到2025年，制造业机 器人密度较2020年实现翻番，服务机器人、特种机器人行业应用深度和广度显著提升，机器人促进经济 社会高质量发展的能力明显增强。11月12日工业和信息化部又印发《人形机器人创新发展指导意见》， 提出人形机器人有望成为继计算机、智能手机、新能源汽车后的颠覆性产品，并明确2025年实现批量生 产。 各项政策加持，热度非凡，行业活动也层出不穷，小编通过网络搜集整理了 未来两周国内外机器人及 人工智能领域行业活动活动榜单 ，供大家参考。 2025.07.07-07.20 机器人及人工智能相关活动预告 1 2025智能机器人关键技术大会 时间： 2025.07.22-07.24 地点： 齐齐哈尔市 主办单位： 《机器人技术与应用》杂志社 2 全国首届人形机器人线缆技术交流大会 时间： 2025.07.07 地点： 江西省吉安县优尔会议室 主办单位： 深圳市机器人特种线缆行业协会 时间： 2025.07.09-07.11 地点： 千叶 ...

特斯拉二季度销量进一步下滑 这么差的数据理论上应该会暴跌才对啊，但特斯拉不一样反而暴涨。美东时间7月2日，特斯拉股价强势反弹4.97%，市值一夜飙升481亿美元（约合人民 币3,450亿元），重新成为全球资本市场的焦点。这场突如其来的暴涨背后，直接归因应该是略超分析师预期，是筑底情绪带来的资金回补。但深层次来 看，应该是对特斯拉AI技术叙事的再次肯定支持，以及对马斯克这个特斯拉最大悬念的期待。或许马斯克会再次带领特斯拉实现困境反转，像过去无数 次那样。 特斯拉发布Q2交付数据：交付38.4万辆，同比下降13.5%，但却高于市场普遍预期的36.5万辆。尤其是相比此前高盛、花旗等多家投行对其"深度衰退"的 预测，这一数据属于典型的"低预期+小超预期"。有市场人士认为，虽然特斯拉的电动车销量增长放缓，但已触底，悲观预期开始修复。 不管别人信不信，但特斯拉头号多头木头姐已经出手了，本周二 "木头姐"凯茜·伍德已经出手增持，她总共购买了56368股特斯拉股票，价值约1791万美 元。 那么特斯拉的故事，马斯克打算还如何书写，是就此平庸下去，还是再次开启魔法时刻，带领特斯拉进入下一个时代？另外，马斯克能兼顾建党吗？ 马斯 ...